Q. BGP Technologies is a fictitious biotech industry that provides pharmaceutical consulting, custom drug manufacturing and a line of consumer medical devices and generic drugs to customers worldwide. It has consulting offices in most of the major cities in the world, with manufacturing plants in the United States, China and Mexico. Recently, the worldwide financial slump has put the industry in a difficult position. Before the downturn, the industry could absorb the litigation costs associated with its operations as part of the normal cost of doing business; now it can no longer afford to do so. BGP Technologies wants to implement illustrate whatever actions it can to avoid or at least minimize some of the legal pitfalls facing it in its worldwide operations.